F-1/A: Gelteq Limited Eyes Nasdaq Listing with Proposed IPO and Resale of Ordinary Shares

Gelteq Limited is seeking to list on the Nasdaq Capital Market through an initial public offering of 1,300,000 Ordinary Shares and a concurrent resale of 1,749,243 Ordinary Shares by existing shareholders.

Summary

• Gelteq Limited, an Australian company, is planning an initial public offering (IPO) in the United States to list its Ordinary Shares on the Nasdaq Capital Market.
• The IPO involves the offering of 1,300,000 Ordinary Shares at an initial public offering price of USD$5.00 per share.
• Concurrently, existing shareholders are offering 1,749,243 Ordinary Shares for resale.
• Gelteq will not receive any proceeds from the sale of shares by the selling shareholders.
• The company intends to use the proceeds from the IPO for working capital purposes, research and development, and sales and marketing initiatives.
• Gelteq is an emerging growth company and a foreign private issuer, which allows it to comply with certain reduced reporting requirements.
• The company's Ordinary Shares are expected to be listed on the Nasdaq Capital Market under the symbol 'GELS', pending approval.
• The company's primary focus is on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products.
• The company's products are edible gels with multiple-ingredient dosage forms, targeting pets, sports, pharmaceutical, over-the-counter, and nutraceutical markets.
• The company has a patent portfolio covering its gel technology and related applications.
• The company has a history of operating losses and expects to incur further losses in the near term.
• The company's financial performance is influenced by economic conditions in the PRC, as it relies on a Chinese manufacturer.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is pursuing growth opportunities and has innovative technology, it also faces significant financial challenges and risks. The sentiment is neutral, reflecting the balance of positive and negative factors.

Positives

• The company is developing innovative gel-based delivery solutions with a wide range of potential applications.
• The company has a patent portfolio covering its gel technology.
• The company is targeting high-growth markets such as nutraceuticals and pet care.
• The company is focusing on out-licensing its technology, which can provide a scalable revenue model.
• The company has a research partnership with Monash University, a leading institution in pharmaceutical science.

Negatives

• The company has a history of operating losses and expects to incur further losses in the near term.
• The company's financial performance is influenced by economic conditions in the PRC, as it relies on a Chinese manufacturer.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.

Risks

• The company may not be able to achieve or sustain profitability.
• The company may not be able to manage its growth effectively.
• The company faces significant competition in its market.
• The company may not be able to protect its intellectual property rights.
• The company's financial performance is influenced by economic conditions in the PRC, as it relies on a Chinese manufacturer.
• The company has a limited number of suppliers for raw materials, which could affect its ability to meet production commitments.
• The company has a history of customers delaying orders due to cash flow difficulties.
• The company may be adversely affected by foreign currency fluctuations.
• The company may be subject to penalties for non-compliance with anticorruption and anti-money laundering laws.
• The company may be adversely impacted if it fails to comply with U.S. and international import and export laws.
• The company may be subject to penalties for failure to comply with laws relating to labor and employment.

Future Outlook

The company expects to manufacture and deliver outstanding orders in the fiscal year ending June 30, 2025. The company expects to finalize a dedicated production line with a GMP certified manufacturer in Melbourne, Australia in the fiscal year ending June 30, 2025 to further enhance production capacity which will avoid future delays.

Industry Context

The announcement relates to the broader industry trends of innovative drug delivery systems, personalized nutrition, and the growing pet care market. The company is positioning itself to capitalize on these trends through its gel-based delivery technology.

Comparison to Industry Standards

• The company competes with other companies in the pharmaceutical market which have novel and innovative drug delivery systems in the pipeline such as transdermal patches, oral films, injection, and chewing gum.
• Competitors include Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP), IntelGenx Technologies Corp. (OTCMKTS: IGXT), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Lexaria Bioscience Corp. (NASDAQ: LEXX), Taro Pharmaceuticals Industries Ltd. (NYSE: TARO), Catalent Inc. (NYSE: CTLT), Insulet Corporation (NASDAQ: CTLT), Nutriband Inc. (NASDAQ: NTRB), Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) and Hempfusion Wellness Inc. (TSE: CBD.U).
• The company is not aware of any companies currently offering drug delivery in a similar gel base as at the date of this prospectus.

Management Changes

Related Party Transactions

• The company has engaged in related party transactions, including loans from directors and entities associated with directors, and a lease agreement with an entity associated with directors.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new Ordinary Shares.
• Shareholders may benefit from the company's growth and increased profitability if the IPO is successful.
• Employees may benefit from increased job opportunities and potential equity ownership.
• Customers may benefit from innovative gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products.

Next Steps

• Obtain approval for listing on the Nasdaq Capital Market.
• Complete the initial public offering.
• Execute on plans to use the IPO proceeds for working capital, research and development, and sales and marketing initiatives.
• File sixth and seventh patent families in the first quarter of the fiscal year ending June 30, 2025.
• Manufacture and deliver outstanding orders in the fiscal year ending June 30, 2025.

Key Dates

Keywords

Gelteq, IPO, Ordinary Shares, Convertible Notes, Gel-based delivery, Pharmaceutical, Nutraceutical, Pet care, Listing, Nasdaq